临床应用口服抗血小板药物与质子泵抑制剂的思考
被引量:6
Combination of antiplatelet drugs and proton pump inhibitors in clinical practice
摘要
大量循证医学证据证实抗血小板治疗能有效降低风险人群的不良心血管事件。然而,伴随抗血小板新药研发,以及双联甚或三联强效方案的应用,
出处
《中国心血管杂志》
2013年第6期412-415,共4页
Chinese Journal of Cardiovascular Medicine
参考文献20
-
1Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/ AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol, 2010,105:2533-2549.
-
2Wiirtz M,Grove EL, Kristcnsen SD, et al. The antiplatelet effectof aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart, 2010,96:368-371.
-
3Chariot M,Grove EL, Hansen PR, ct al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ, 2011,342 : d2690.
-
4Gilard M,Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coil Cardiol, 2008,51:256-260.
-
5Juurlink DN,Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ, 2009,180:713-718.
-
6Ho PM,Maddox TM, Wang L, associated with concomitant use et al. Risk of adverse outcomes of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA, 2009,301 : 937 -944.
-
7Stockl KM,Le L, Zakharyan A, et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med, 2010,170:704-710.
-
8Siner-Matula JM, Jilma B, Schrtir K, et al. Effect of proton pump inhibitors on clinical outcome in patients treated with elopidogrel: asystematic review and meta-analysis. J Thromb Haemost, 2010,8 : 2624-2641.
-
9Hulot JS,Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19 * 2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coil Cardiol, 2010,56 : 134-143.
-
10O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet, 2000,374:989-997.
同被引文献87
-
1刘庆华,何礼贤.胃肠道和呼吸机相关性肺炎[J].中国呼吸与危重监护杂志,2003,2(5):317-318. 被引量:18
-
2张萌,荀轶文,傅研.呼吸机相关性肺炎临床预防指南——加拿大危重病学会和危重病临床试验组制定[J].世界急危重病医学杂志,2005,2(2):668-669. 被引量:9
-
3李军,魏庆旺,张鉴.注射用奥美拉唑钠溶液的稳定性考察[J].中国医院药学杂志,2005,25(8):775-776. 被引量:42
-
4卢雅丕,任建林.NSAIDs相关性胃肠病[J].世界华人消化杂志,2005,13(21):2597-2600. 被引量:10
-
5张俊松,戚燕,王晓利,吴松.注射用奥美拉唑溶液配伍稳定性研究[J].中国药师,2007,10(4):352-354. 被引量:21
-
6Michos ED, Ardehali R, Blumenthal RS, et al.Aspirin and clopidogrel resistance[J].Mayo Clin Proc, 2006, 81 (4) : 518.
-
7抗血小板药物消化道损伤的预防和治疗中国专家共识组.抗血小板药物消化道损伤的预防和治疗中国专家共识:2012年更新版[J].中华内科杂志,2013,53(2):264.
-
8Petersen KU.Relevance of metabolic activation pathways: the example of clopidogrel and prasugrel[J]. Arzneimittel- forschung, 2009,59(5) : 213.
-
9Juurlink DN, Gomes T, Ko DT, et al.A population-based study of the drug interaction between proton pump inhibi- tors and clopidogrel[J].CMA J, 2009,180(7) :713.
-
10Hsiao FY, Mullins CD, Wen YW, et al.Relationship be- tween cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome[J]. Pharmacoepidemiol Drug Saf,2011,20(10) : 1 043.
引证文献6
-
1孔令提,刘冬,宋春丽,邢蓉.抗血小板药物临床个体化给药中存在的问题及其研究进展[J].中国药房,2015,26(20):2878-2880. 被引量:2
-
2林海.内镜介入联合质子泵抑制剂治疗消化性溃疡合并上消化道出血疗效观察[J].华夏医学,2015,28(4):65-68. 被引量:7
-
3孙敏,黄坤明,司继刚.临床使用质子泵抑制剂的药学监护[J].河北医药,2016,38(2):275-278. 被引量:11
-
4殷勤,盛雪鹤.2008年和2013年皖南医学院第二附属医院临床用药变化情况分析[J].中国医院用药评价与分析,2016,16(2):224-227.
-
5邓靖中.我院质子泵抑制剂的合理用药评价与管控[J].中国药房,2018,29(13):1819-1823. 被引量:15
-
6李全良,夏海建,林郁,黄富宏,焦乾升.扬州45家基层医院质子泵抑制剂合理用药分析[J].中国药业,2018,27(4):94-96. 被引量:4
二级引证文献37
-
1彭智祥,李雪,王亚敏,赵诗云,吴东风,张娣.天然产物抗血小板聚集作用的研究进展[J].沈阳药科大学学报,2019,36(12):1133-1144. 被引量:5
-
2王齐,李琴.埃索美拉唑联合生长抑素治疗藏区上消化道大出血的可行性分析[J].中国现代医生,2017,55(8):31-34. 被引量:3
-
3孙乐乐,郑雪,于琨.注射用兰索拉唑致发热、寒战1例[J].中国医院药学杂志,2017,37(14):1418-1418.
-
4蔡黎.质子泵抑制剂在临床使用中的应用分析[J].北方药学,2017,14(9):100-101. 被引量:1
-
5汤盛新.介入治疗在不明原因上消化道出血中的应用及疗效分析[J].黑龙江医药,2017,30(2):416-418.
-
6谭震宇.艾司奥美拉唑钠与兰索拉唑治疗消化道溃疡所致急性上消化道出血的疗效对比[J].中国实用医药,2017,12(33):99-101. 被引量:25
-
7刘晓川,翁艳,贾志伟.内镜下止血联合质子泵抑制剂泵入在中老年消化性溃疡并发出血中应用[J].创伤与急危重病医学,2018,6(4):214-216. 被引量:2
-
8李语玲,马雅斌,石卫峰.临床药师对1例甲状腺相关性眼病患者的用药监护[J].中南药学,2018,16(8):1045-1048. 被引量:2
-
9鞠晓宇,赵越,程杰,赵倩,关胜江.质子泵抑制剂临床合理应用与处方精简[J].中国临床药学杂志,2018,27(4):268-272. 被引量:3
-
10钱跹,成丹,陈安妮,张国庆,战旗.艾司奥美拉唑在肝胆外科围术期的合理应用分析[J].药学实践杂志,2018,36(6):557-560. 被引量:4
-
1陈玲,邹栩.2008年FDA批准新药24个[J].中国药科大学学报,2009,40(1).
-
2薛东莉.研究口服抗血小板药物在冠心病治疗中的应用效果[J].中华临床医师杂志(电子版),2016,10(7):109-110. 被引量:4
-
3阿斯利康口服抗血小板药物Brilinta临床3期试验结果[J].临床合理用药杂志,2009,2(11):56-56.
-
4胡发明.口服抗血小板药物与抗凝剂防治缺血性心脏病[J].国外医药(合成药.生化药.制剂分册),2001,22(2):89-90. 被引量:1
-
5孙梅.抗血小板药替格瑞洛的研究进展[J].天津药学,2016,28(6):60-62. 被引量:5
-
6王吉云.Prasugrel进入Ⅲ期临床[J].国外药讯,2004(12):7-8.
-
7郭艺芳,金雅丽.氯吡格雷联合质子泵抑制剂可增加再梗死的风险[J].临床荟萃,2009,24(14):1212-1212. 被引量:2
-
8国外新批准上市的药物新制剂新剂型(158)[J].中国制药信息,2011,27(3):24-26.
-
9菅鑫妍(编译).替卡格雷首次显示可以比氯吡格重更能降低急性冠脉综合征患者的心血管死亡[J].今日药学,2009,19(8).
-
10姜攀.新型血小板聚集抑制剂研究进展[J].中国药学杂志,2013,48(3):230-233.